Brett Villagrand
Associate Director, Strategy, BioOncology, Genentech
BORN: Australia; has lived in four countries
CAN'T LIVE WITHOUT: Rugby
On brand success:
Brett Villagrand
|
Herceptin revolutionized the way to treat HER2-positive breast cancer. I've been fortunate enough to work on that brand for
the last three years—and to be here at Genentech at the right time. We've been fairly successful, with sales at around $1.3
billion. It's been a roller coaster ride to get there because the brand's more than doubled its growth over the last four
or five years. Now we're facing competition for the first time. But despite the entry of a new competitor, we've been able
to keep them to less than 5 percent of the market. Far from resting, we've instead put a number of things in place that will
help us maintain our leadership role in that area.
PharmExec Blog
Follow Us
RSS
Bookstore
